Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer

Figure 1

In vivo anti-tumor activity of wt-p53 loaded gelatin nanoparticles. (a) Volume change as a function of time showing 27.9, 38.3* and 50.1%** reduction in tumor growth on day 33 for wt-p53 loaded SH-Gel, SH-Gel-PEG and SH-Gel-PEG-peptide nanoparticle treated tumor respectively. (b) Tumor weights on day 7, 18 and 33. Results are presented as mean ± SD (n = 3 for day 7 and 18; n = 6 for day 33) (* p < 0.05; ** p < 0.01; *** p < 0.001).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us